Staff Correspondent ;
Summit Technolpolis, Oryx Biotech Holdings and BHTPA signed a tripartite agreement worth USD 300 Million on Tuesday to set up a Plasma Fractionation Plant in Block II of Summit Technopolis to produce plasma derivatives also known as Life Saving Therapeutics and other related products – making it the first biotech investment in Bangladesh, announced a spokeswoman.
With the attack of COVID-19 this project was a timely investment for Bangladesh’s healthcare research and service sectors, she said, adding that it is expected that about 2,000 high-value science graduates will be employed to produce therapeutics such as Albumin, Immunoglobulin and Coagulation factor VIII.
Muhammed Aziz Khan, Founder Chairman of Summit said, “We are pleased to activate the nation’s first and largest biotech investment of about USD 300 million on 25 acres of land and building provided by Summit Technopolis. It is most gratifying that this milestone plasma fractionation project which will open new horizons in Bangladesh’s development is happening in this auspicious year of Bangabandhu’s birth centenary.”
The agreement signing was witnessed by the State Minister, Ministry of Power, Energy and Mineral Resources Nasrul Hamid MP, ICT State Minister Zunaid Ahmed Palak, MP, Senior Secretary of ICT Division N M Zeaul Alam PAA, Managing Director of Bangladesh Hi-Tech Park Authority (BHTPA) Hosne Ara Begum ndc.
The ceremony was virtually attended by Muhammed Aziz Khan, Vice-Chairmen of Summit Group Jafer Ummeed Khan, Latif Khan and Farid Khan.
Summit Technopolis Limited, a Public Private Partnership (PPP), is the concessionaire for developing infrastructure for hi-tech industry comprising of Information Technology (IT), Information Technology Enabled Services (ITeS), bio-tech, non-polluting manufacturing assembly lines and precision engineering companies, in the 91 acres area in Bangabandhu Hi- Tech City, Kaliakoir, Gazipur. Summit Technopolis leased under the provision to design, build, finance, own, operate and transfer to the government on completion of 60 years lease period.
Oryx Biotech Holdings, parent company of Oryx Bio-Tech Ltd., is a China-based biological product developer. With support of our partner, the NASDAQ USA-listed company namely China Biologic Products Holdings, Inc., which is the most technologically advanced and one of the largest Life Saving Therapeutics manufacturers in China.